SynthesisBMC psychiatry2026
Investigating event-related potential (ERP) deviations in clinical high-risk populations for psychosis: a systematic review and meta-analysis.
Synthesis in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveIndividuals at clinical high risk for psychosis exhibit cognitive and neurophysiological abnormalities that may predict transition to schizophrenia. Event-related potentials (ERPs), including mismatch negativity (MMN), P300, and N100, have been proposed as candidate biomarkers. This systematic review and meta-analysis aimed to synthesize evidence on ERP alterations in CHR populations compared with healthy controls (HCs) and to evaluate their predictive value for transition.
methodsFollowing PRISMA guidelines, PubMed and Medline were systematically searched from January 1996 to March 2025. Studies reporting ERP data in CHR and HC participants, and longitudinal studies distinguishing converters (CHR-T) from non-converters (CHR-NT), were included. Data extraction and quality assessment followed Cochrane standards, and pooled effect sizes were estimated using random- or fixed-effects models.
resultsThirty-six studies were included. Compared with HCs, CHR individuals demonstrated significantly reduced P300 amplitude (MD (95%CI) = -2.35 (-3.31, -1.39), p < 0.05) and attenuated duration- and frequency-deviant MMN (MD (95%) = 0.31 (0.20, 0.43), p < 0.01), whereas N100 showed no significant group differences. In longitudinal analyses, only duration-deviant MMN differentiated CHR converters from non-converters (p < 0.05). Sensitivity analyses confirmed robustness of the findings.
conclusionsERP abnormalities, particularly reduced duration-deviant MMN, represent promising biomarkers for early detection of psychosis risk and may aid in risk stratification and intervention planning. These results highlight the potential utility of ERPs as clinically accessible, low-cost neurophysiological tools for predicting transition in CHR populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.